Latest round: IPO. Guido Baechler is the CEO of Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer.
Guido Baechler is the CEO of Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer. The company is preparing for U.S. FDA trials in 2025 for its mRNA-based next-generation colorectal cancer screening test, aiming for substantial growth in global markets and entry into the U.S. market.
Full founder directory · Investor directory · Company funding database · Fundraising library